Company intelligence / Profile preview

Carephar

Ownership: Private
Development stage: Commercial

Overview

Carephar has achieved commercial approval in China for keverprazan hydrochloride for duodenal ulcer and reflux esophagitis. The company has multiple innovative drugs in clinical and preclinical stages across cardiovascular, cerebrovascular, digestive diseases, oncology/immunotherapy, and chronic diseases. Its pipeline includes small molecules, stem cell therapies, and traditional Chinese medicines with several programs in late-stage clinical development or approved status.

Therapeutic areas: GastroenterologyMen's HealthInfectious Diseases
Modalities: Small moleculeMesenchymal stem cell therapyTraditional Chinese medicineChemical drugBiologic
Industry: Biotech

Drug pipeline

14 assets

keverprazan

13 more assets in the full pipeline.

Partnerships

Fosun Pharma – global co-development and exclusive commercialization partnership for Keverprazan Hydrochloride

Beyond the preview

Go deeper on Carephar.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Carephar.